Literature DB >> 2844645

Anaplasia in unilateral Wilms' tumor: a report from the National Wilms' Tumor Study Pathology Center.

C W Zuppan1, J B Beckwith, D W Luckey.   

Abstract

Fifty-eight unilateral anaplastic Wilms' tumors entered on the Third National Wilms' Tumor Study (NWTS-3) were reviewed. The favorable outcome of stage I anaplastic tumors was confirmed. In stage II-IV tumors, the extent and severity of anaplasia were not of prognostic importance. However, two histologic features were correlated with extremely poor outcome; anaplasia in extrarenal tumor sites (P = .016) and predominantly blastemal tumor pattern (P = .020). The importance of these features in predicting relapse and death for children with anaplastic Wilms' tumor was supported by the study of 47 additional anaplastic Wilms' tumor cases from NWTS-2. These results emphasize the importance of examining sites of extrarenal spread in anaplastic Wilms' tumors. Cytologic criteria for anaplasia and clues to its recognition are reviewed, and the potential clinical and biological implications of our findings are discussed.

Entities:  

Mesh:

Year:  1988        PMID: 2844645     DOI: 10.1016/s0046-8177(88)80152-7

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  14 in total

Review 1.  renal tumors and tumor-like lesions in pediatric patients.

Authors:  J M Kissane; L P Dehner
Journal:  Pediatr Nephrol       Date:  1992-07       Impact factor: 3.714

Review 2.  Candidate genes and potential targets for therapeutics in Wilms' tumour.

Authors:  Christopher Blackmore; Max J Coppes; Aru Narendran
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

3.  Antioxidant and glutathione-associated enzymes in Wilms' tumour after chemotherapy.

Authors:  J Gajewska; M Szczypka; T Izbicki; T Klepacka; T Laskowska-Klita
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study.

Authors:  Najat C Daw; Yueh-Yun Chi; Yeonil Kim; Elizabeth A Mullen; John A Kalapurakal; Jing Tian; Geetika Khanna; James I Geller; Elizabeth J Perlman; Peter F Ehrlich; Anne B Warwick; Paul E Grundy; Conrad V Fernandez; Jeffrey S Dome
Journal:  Eur J Cancer       Date:  2019-07-17       Impact factor: 9.162

5.  Clinicopathological profile of Wilms' tumor.

Authors:  L Paul; D Thaver; S Muzaffar; I N Soomro; Z Nazir; S H Hasan
Journal:  Indian J Pediatr       Date:  2000-10       Impact factor: 1.967

6.  Anaplastic histology Wilms' tumors registered to the Japan Wilms' Tumor Study Group are less aggressive than that in the National Wilms' Tumor Study 5.

Authors:  Takaharu Oue; Tsugumichi Koshinaga; Tetsuya Takimoto; Hajime Okita; Yukichi Tanaka; Miwako Nozaki; Masayuki Haruta; Yasuhiko Kaneko; Masahiro Fukuzawa
Journal:  Pediatr Surg Int       Date:  2016-07-29       Impact factor: 1.827

7.  Distinctive properties of an anaplastic Wilms' tumor and its associated epithelial cell line.

Authors:  D J Hazen-Martin; G G Re; A J Garvin; D A Sens
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

8.  Recent experience with Wilms' tumor: 1978-1991.

Authors:  R C Shamberger; R M Macklis; S E Sallan
Journal:  Ann Surg Oncol       Date:  1994-01       Impact factor: 5.344

Review 9.  Biomarkers for Wilms Tumor: A Systematic Review.

Authors:  Eugene B Cone; Stewart S Dalton; Megan Van Noord; Elizabeth T Tracy; Henry E Rice; Jonathan C Routh
Journal:  J Urol       Date:  2016-05-31       Impact factor: 7.450

10.  Pleuropulmonary blastoma: a report on 350 central pathology-confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry.

Authors:  Yoav H Messinger; Douglas R Stewart; John R Priest; Gretchen M Williams; Anne K Harris; Kris Ann P Schultz; Jiandong Yang; Leslie Doros; Philip S Rosenberg; D Ashley Hill; Louis P Dehner
Journal:  Cancer       Date:  2014-09-10       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.